ICER to assess gene therapy for beta thalassaemia


24 November 2021 - Report will be subject of New England CEPAC meeting in June 2022; draft scoping document open to public comment until 16 December 2021.

The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of betibeglogene autotemcel (Zynteglo/LentiGlobin, bluebird bio) for the treatment of beta thalassaemia.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder